Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial (2023)

First Author: Bevers L

Attributed to: Paediatric and adolescent infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciad346

PubMed Identifier: 37280040

Publication URI: http://europepmc.org/abstract/MED/37280040

Type: Journal Article/Review

Parent Publication: Clinical Infectious Diseases

Issue: 9